ClinicalTrials.gg
TerminatedNCT02647762Updated Dec 19, 2020

CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid Arthritis

A Phase 3 interventional study of CF101 1 mg and CF101 2 mg in Rheumatoid Arthritis, sponsored by Can-Fite BioPharma. Terminated at 35 sites in 7 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-12-19.

Sponsored by Can-Fite BioPharma · Phase 3, Interventional, and Treatment

Why this study was terminated
Interim analysis results

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
244
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 115 studies in Arthritis, Rheumatoid with a site in Romania — 4 open to participants now, 8 under way, 1 of them phase 3. Arthritis, Rheumatoid · Romania.

Enrollment
75th of 110
244 · median 371
Started
2017
with 3 others
Phase 3
46 of 115
none open now
Registered
93rd of 115
by date

Among the 115 studies in Arthritis, Rheumatoid with a site in Romania, this one is the 75th largest by enrollment of the 110 interventional ones that give a count, is one of 4 that started in 2017, is one of 46 in phase 3, and was the 93rd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 115 studies in Arthritis, Rheumatoid with a site in Romania are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Romania have not opened yet or have stopped. Only those recruiting at a site in Romania →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies in Arthritis, Rheumatoid with a site in Romania, or all of them as a file.
02

Study summary

This trial will test the hypothesis that the administration of CF101, a novel anti-inflammatory agent, to patients with rheumatoid arthritis will relieve signs and symptoms of the disease. CF101 effect will be in comparison to MTX in this study population.

Read the detailed description

This will be a randomized, double-blind, active- and placebo-controlled, parallel-group study in subjects with clinically active RA but who are MTX-naïve. Subjects who meet enrollment criteria will be randomized to 1 of 4 groups in a 2:2:2:1 ratio: CF101 1 mg, CF101 2 mg, MTX, or matching placebo tablets. CF101 or matching placebo will be administered every 12 hours for up to 24 weeks on treatment. MTX or matching placebo will be administered once a week Screening examinations will occur within 6 weeks prior to dosing. The following conventional drugs for RA treatment must be stable for the respective designated periods prior to the Screening Visit and must remain so during protocol participation: nonsteroidal anti-inflammatory drugs (NSAIDS), and corticosteroids for >1 month. All subjects will receive oral folate (minimum dose 5 mg/week) or oral folinic acid (up to 10 mg/week), based on the Investigator's preference.

Disease activity will be assessed using swollen and tender joint counts, erythrocyte sedimentation rate (ESR), and CRP. Efficacy will be assessed by Disease Activity Score 28 using the erythrocyte sedimentation rate (DAS28-ESR), ACR response criteria and European League Against Rheumatism (EULAR) response criteria : swollen and tender joint counts, physician global assessment (by visual analog scale, patient global assessment , patient reported pain, a Health Assessment Questionnaire (HAQ) Disability Index (DI) , Westergren ESR levels, and CRP levels. Assessments will occur at Screening, Baseline (Week 0), and Weeks 4, 8, 12 16, 20, and 24. At Weeks 12, 16, and 20, any subject who has not experienced at least 20% improvement in both the number of swollen and number of tender joints will be given rescue therapy with open-label oral MTX and followed through Week 24.

PK will be assessed in a subgroup of approximately 100 subjects at Week 0, Week 8, and Week 12. All subjects in the PK cohort will have samples collected for PK at time 0, and each subject will have additional samples drawn at 2 of the following post-dose time points: 1, 2, 3, 4, 6, and 8 hours. Whole blood sample for A3AR expression will be assessed in approximately 100 subjects at selected sites at Screening and Week 12, or end of dosing, if occurring before Week 12.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females ages 18-75 years.
  2. Meet the criteria of the American College of Rheumatology for RA (Arnett FC et al. Arthritis Rheum 1988;31:315-324, Appendix 1).
  3. Not bed- or wheelchair-bound.
  4. Active RA, as indicated by EULAR Disease Activity Score (Fransen, vanRiel, 2005, DAS28, 2015) (DAS28) >3.2.
  5. Demonstrate at least 6 swollen and at least 6 tender joints.
  6. If taking an NSAID, dose has been stable for at least 1 month prior to the Screening Visit, and will remain unchanged during protocol participation.
  7. If taking an oral , dose is \<10 mg/day prednisone or equivalent, has been stable for at least 1 month prior to the Screening Visit, and will remain unchanged during protocol participation.
  8. In the Investigator's opinion, the ability to understand the nature of the study and any hazards of participation, and to communicate satisfactorily with the Investigator and to participate in, and to comply with, the requirements of the entire protocol.
  9. Negative Screening serum pregnancy test for female subjects of .
  10. Females of childbearing potential must utilize, throughout the course of the trial, 2 methods of deemed adequate by the Investigator (for example, oral contraceptive pills plus a barrier method).
  11. All aspects of the protocol explained and written obtained.

Exclusion criteria

Exclusion Criteria:

  1. Prior receipt of MTX.
  2. Prior receipt of >1 regimen of synthetic small-molecule DMARDs.
  3. Receipt of any non-MTX synthetic small-molecule DMARDs (including but not limited to sulfasalazine, chloroquine/hydroxychloroquine, azathioprine, and/or leflunomide) for at least 1 month prior to the Screening Visit or concomitantly during the trial.
  4. Receipt of tofacitinib at any time during the 4-week period prior to the Screening Visit or concomitantly during the trial.
  5. Receipt of a biologic anti-rheumatic agent (including, but not limited to, etanercept, abatacept, infliximab, golimumab, adalimumab, tocilizumab, certolizumab, and rituximab) at any time prior to or concomitantly during the trial.
  6. Levels of rheumatoid factor (RF) and anti-cyclic citrullinated peptide (CCP) antibody that are both >3 times the upper limit of the laboratory normal value at the Screening Visit.
  7. Receipt of parenteral or intra-articular during the 1 month prior to the Screening Visit.
  8. Participation in a previous trial CF101 trial.
  9. Presence or history of uncontrolled arterial hypertension or symptomatic hypotension.
  10. Heart disease which is, in the Investigator's judgment, or unstable, including coronary artery disease, congestive heart failure, uncontrolled arrhythmia, or other significant findings on Screening (ECG).
  11. Clinical laboratory abnormalities at the Screening Visit as follows:

    1. level \<9.0 gm/dL
    2. count \<125,000/mm3
    3. White blood cell (WBC) count \<3000/mm3
    4. Serum creatinine level outside the central laboratory's normal limits
    5. Liver aminotransferase ( and/or AST) levels greater than 2 times the central laboratory's .
  12. Known or suspected immunodeficiency or positivity.
  13. Pregnancy, lactation, or inadequate as judged by the Investigator.
  14. Participation in another drug or vaccine trial concurrently or within 30 days prior to Screening.
  15. Active drug or alcohol dependence.
  16. History of within the past 2 years (excluding excised basal or squamous cell carcinoma of the skin).
  17. Significant acute or chronic medical or psychiatric illness that, in the judgment of the Investigator, could compromise subject safety, limit the subject's ability to complete the study, and/or compromise the objectives of the study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
244 participants (actual)

Study arms

  • Experimental
    CF101 1mg

    CF101 1mg, orally q12 hours

    Drug: CF101 1 mg

  • Experimental
    CF101 2mg

    CF101 2mg, orally q12 hours

    Drug: CF101 2 mg

  • Active comparator
    MTX once weekly

    MTX 5 mg tablets, given once weekly at 10 mg/week (2 tablets) for the first 2 weeks, then 15 mg/week (3 tablets) for the next 2 weeks, then 20 mg/week (4 tablets) thereafter.

    Drug: MTX

  • Placebo comparator
    Placebo

    Placebo control , orally q12 hours

    Drug: Placebo

Interventions

  • CF101 tablets, 1mg BID for 12 weeks

    Also known as: IB-MECA, Piclidenosone

  • CF101 tablets, 2 mg BID for 12 weeks

    Also known as: IB-MECA, Piclidenosone

  • DrugPlacebo

    Placebo tablets, 1mg BID for 12 weeks

  • DrugMTX

    MTX 5 mg tablets, given once weekly at 10 mg/week (2 tablets) for the first 2 weeks, then 15 mg/week (3 tablets) for the next 2 weeks, then 20 mg/week (4 tablets) thereafter, for 12 weeks.

06

What researchers measure

Primary outcomes

  1. Efficacy of oral CF101, BID for 12 weeks to subjects with active rheumatoid arthritis (RA) relative to oral methotrexate (MTX) as assessed by the proportion of subjects achieving a Disease Activity Score (DAS) of Low Disease Activity (LDA)

    Proportion of subjects achieving Disease Activity Score (DAS) (based on Erythrocyte Sedimentation Rate) of Low Disease Activity (\<3.2, where lower scores indicate lower disease activity) at Week 12

    Time frame: 12 weeks

  2. Assess the adverse event profile of daily oral CF101 under the conditions of the trial

    Nature, incidence and severity of treatment-emergent adverse events (TEAEs)

    Time frame: 24 weeks

  3. Describe the pharmacokinetics (PK) of CF101 under the conditions of the trial

    Plasma CF101 levels will be determined

    Time frame: 24 weeks

Secondary outcomes

  1. Determine the efficacy of oral CF101 when administered daily for 24 weeks to subjects with active RA relative to oral MTX, as assessed by the proportion of subjects achieving DAS remission

    Change and percent change from baseline in DAS28

    Time frame: 24 weeks

  2. Explore the relationship between whole blood adenosine A3 receptor (A3AR) expression and treatment response

    A3AR expression will be assessed on whole blood samples

    Time frame: 24 weeks

07

Study locations

35 sites
  • Can-Fite Investigational Site #252
    Banja Luka, Bosnia and Herzegovina
  • Can-Fite Investigational Site #256
    Banja Luka, Bosnia and Herzegovina
  • Can-Fite Investigational Site #253
    Mostar, Bosnia and Herzegovina
  • Can-Fite Investigational Site #251
    Sarajevo, Bosnia and Herzegovina
  • Can-Fite Investigational Site #255
    Tuzla, Bosnia and Herzegovina
  • Can-Fite Investigational Site #751
    Barrie, Canada
  • Can-Fite Investigational Site #309
    Ashkelon, Israel
  • Can-Fite Investigational Site #302
    Haifa, Israel
  • Can-Fite Investigational Site #581
    Chisinau, Moldova, Republic of
  • Can-Fite Investigational Site #582
    Chisinau, Moldova, Republic of
  • Can-Fite Investigational Site #583
    Chisinau, Moldova, Republic of
  • Can-Fite Investigational Site #401
    Białystok, Poland
  • Can-Fite Investigational Site #402
    Bochnia, Poland
  • Can-Fite Investigational Site #403
    Poznań, Poland
  • Can-Fite Investigational Site #559
    Brăila, Romania
  • Can-Fite Investigational Site #551
    Bucuresti, Romania
  • Can-Fite Investigational Site #552
    Bucuresti, Romania
  • Can-Fite Investigational Site #553
    Bucuresti, Romania
  • Can-Fite Investigational Site #562
    Bucuresti, Romania
  • Can-Fite Investigational Site #564
    Bucuresti, Romania
  • Can-Fite Investigational Site #565
    Bucuresti, Romania
  • Can-Fite Investigational Site #558
    Constanţa, Romania
  • Can-Fite Investigational Site #563
    Craiova, Romania
  • Can-Fite Investigational Site #561
    Iaşi, Romania
  • Can-Fite Investigational Site #555
    Oradea, Romania
  • Can-Fite Investigational Site #554
    Timişoara, Romania
  • Can-Fite Investigational Site #212
    Belgrad, Serbia
  • Can-Fite Investigational Site #223
    Bor, Serbia
  • Can-Fite Investigational Site #219
    Kragujevac, Serbia
  • Can-Fite Investigational Site #215
    Niš, Serbia
  • Can-Fite Investigational Site #213
    Novi Sad, Serbia
  • Can-Fite Investigational Site #222
    Pirot, Serbia
  • Can-FIte Investigational Site #221
    Sremska Mitrovica, Serbia
  • Can-Fite Investigational Site #220
    Zrenjanin, Serbia
  • Can-Fite Investigational Site #214
    Šabac, Serbia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2017 to primary completion in Nov 2020, 37 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2015
First posted
Jan 6, 2016
StartActual
Oct 30, 2017
Primary completionActual
Nov 30, 2020
CompletionActual
Nov 30, 2020
Last update
Dec 19, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02647762
Lead sponsor
Can-Fite BioPharma
Responsible party
Sponsor
First posted
Jan 6, 2016
Start date
Oct 30, 2017
Primary completion
Nov 30, 2020
Completion
Nov 30, 2020
Last update
Dec 19, 2020

Study contacts

Michael H Silverman, MD
study director · Can-Fite BioPharma

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CF101

Start the discussion